Company Overview
3B Blackbio Dx Limited manufactures and sells molecular diagnostic kits in India. The company designs, develops, manufactures and commercializes qPCR assays, rapid diagnostic tests, NGS-based diagnostic kits, digital PCR assays, and nucleic acid extraction solutions for reliable testing of patient samples, as well as offers oncology and hematology, antimicrobial resistance, infectious diseases, human genetics, extraction, and rapid antigen kits under the TRUPCR, TRUNGS, and TRURAPID brand names; and technical support and training services. 3B Blackbio Dx Limited was incorporated in 1972 and is headquartered in Bhopal, India.
Why Investors Should Care
Generates a return on equity of 18.5%, reflecting efficient use of shareholder capital.
Revenue has grown at a 20.1% CAGR over the past five years.
Trades at a P/E of 20.5, below the sector median of 35.9.
Maintains a net profit margin of 36.3%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹142.00 Cr (+47.9% YoY); net profit ₹60.00 Cr.
- Trailing 12 Months Year-on-year growth — revenue +50.6%, earnings -29.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.1%, profit CAGR -12.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.06% |
| 1 Year: | 50.60% |
Compounded Profit Growth
| 5 Years: | -12.05% |
| 1 Year: | -29.00% |
Stock Price Performance
| 1 Year: | +3.64% |
| 6 Months: | -0.43% |
| 3 Months: | +5.77% |
| 1 Month: | -3.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)41.09 · Neutral
P/E of 20.50 is below the sector median of 35.90 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 36.3%.
- Compounding revenue at 20.1% over 5 years.
- Generates positive free cash flow.
CONS
- Earnings shrank at -12.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3BBLACKBIO 3B Blackbio Dx Limited NSEPHARMA | 1,349.30 | 20.50 | - | 0.31% | - | 18.46% | 20.06% | -12.05% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,758.00 | 34.88 | ₹4.22 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,162.00 | 83.32 | ₹2.43 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,615.30 | 73.73 | ₹1.76 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,135.00 | 25.30 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 634.25 | 165.17 | ₹1.10 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,604.50 | 52.35 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,002.50 | 98.99 | ₹1.08 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,330.90 | 31.92 | ₹1.08 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.11 Cr | 14.28 Cr | 19.18 Cr | 17.67 Cr | 23.00 Cr | 19.43 Cr | 29.15 Cr | 25.39 Cr | 22.50 Cr | 22.23 Cr | 33.90 Cr | 50.35 Cr | 35.43 Cr |
| Operating Expenses | 10.65 Cr | 7.84 Cr | 11.39 Cr | 8.80 Cr | 13.12 Cr | 8.48 Cr | 12.98 Cr | 10.32 Cr | 14.58 Cr | 10.40 Cr | 19.17 Cr | 28.63 Cr | 26.94 Cr |
| Operating Income | 7.25 Cr | 6.25 Cr | 7.55 Cr | 8.55 Cr | 9.58 Cr | 10.68 Cr | 15.90 Cr | 14.80 Cr | 7.64 Cr | 11.55 Cr | 14.15 Cr | 21.34 Cr | 4.60 Cr |
| EBITDA | 7.46 Cr | 6.44 Cr | 7.79 Cr | 8.87 Cr | 9.88 Cr | 10.95 Cr | 16.17 Cr | 15.07 Cr | 7.92 Cr | 11.83 Cr | 14.73 Cr | 21.72 Cr | 8.49 Cr |
| Interest Expense | 4.00 L | 2.00 L | 4.00 L | 3.00 L | 4.00 L | 1.00 L | 3.00 L | 2.00 L | 4.00 L | 1.00 L | 4.00 L | 9.00 L | 10.00 L |
| Pretax Income | 8.36 Cr | 9.19 Cr | 10.26 Cr | 11.15 Cr | 13.73 Cr | 14.36 Cr | 19.31 Cr | 17.79 Cr | 12.54 Cr | 15.86 Cr | 19.62 Cr | 26.84 Cr | 14.65 Cr |
| Tax Provision | 3.16 Cr | 1.98 Cr | 2.67 Cr | 2.64 Cr | 4.94 Cr | 3.06 Cr | 4.44 Cr | 4.30 Cr | 4.50 Cr | 3.22 Cr | 4.58 Cr | 4.40 Cr | 4.85 Cr |
| Net Income | 5.19 Cr | 7.21 Cr | 7.58 Cr | 8.51 Cr | 8.79 Cr | 11.30 Cr | 14.87 Cr | 13.49 Cr | 8.04 Cr | 12.65 Cr | 15.04 Cr | 22.44 Cr | 9.81 Cr |
| Diluted EPS | 7.72 | 9.71 | 10.46 | 10.16 | 10.33 | 12.97 | 17.07 | 15.61 | 9.79 | 14.67 | 17.14 | 25.32 | 11.14 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.00 Cr | 17.00 Cr | 16.00 Cr | 23.00 Cr | 23.00 Cr | 29.00 Cr | 227.00 Cr | 81.00 Cr | 62.00 Cr | 74.00 Cr | 96.00 Cr | 142.00 Cr |
| Operating Expenses | 18.00 Cr | 16.00 Cr | 14.00 Cr | 18.00 Cr | 16.00 Cr | 20.00 Cr | 77.00 Cr | 44.00 Cr | 33.00 Cr | 41.00 Cr | 46.00 Cr | 85.00 Cr |
| Operating Income | 1.00 Cr | 2.00 Cr | 3.00 Cr | 5.00 Cr | 6.00 Cr | 8.00 Cr | 149.00 Cr | 36.00 Cr | 28.00 Cr | 32.00 Cr | 49.00 Cr | 52.00 Cr |
| EBITDA | 1.00 Cr | 2.00 Cr | 3.00 Cr | 5.00 Cr | 7.00 Cr | 9.00 Cr | 150.00 Cr | 37.00 Cr | 29.00 Cr | 33.00 Cr | 50.00 Cr | 57.00 Cr |
| Interest Expense | 1.00 Cr | 1.00 Cr | 1.00 Cr | 1.00 Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pretax Income | 0 | 0 | 1.00 Cr | 5.00 Cr | 7.00 Cr | 10.00 Cr | 152.00 Cr | 43.00 Cr | 35.00 Cr | 44.00 Cr | 64.00 Cr | 77.00 Cr |
| Tax Provision | 0 | 0 | 19.00 L | 1.20 Cr | 1.75 Cr | 2.30 Cr | 38.00 Cr | 11.18 Cr | 9.45 Cr | 12.32 Cr | 16.00 Cr | 16.94 Cr |
| Net Income | 0 | 0 | 1.00 Cr | 3.00 Cr | 5.00 Cr | 8.00 Cr | 114.00 Cr | 32.00 Cr | 26.00 Cr | 32.00 Cr | 48.00 Cr | 60.00 Cr |
| Diluted EPS | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 68.27 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 25.00 Cr | 24.00 Cr | 26.00 Cr | 30.00 Cr | 36.00 Cr | 45.00 Cr | 194.00 Cr | 192.00 Cr | 214.00 Cr | 248.00 Cr | 296.00 Cr | 378.00 Cr |
| Total Equity | 10.00 Cr | 10.00 Cr | 11.00 Cr | 18.00 Cr | 22.00 Cr | 32.00 Cr | 132.00 Cr | 153.00 Cr | 194.00 Cr | 223.00 Cr | 269.00 Cr | 325.00 Cr |
| Total Debt | 8.00 Cr | 8.00 Cr | 9.00 Cr | 6.00 Cr | 6.00 Cr | 4.00 Cr | 2.00 Cr | 3.00 Cr | 2.00 Cr | 1.00 Cr | 0 | 3.00 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 0 | 1.00 Cr | 1.00 Cr | 2.00 Cr | 4.00 Cr | 7.00 Cr | 98.00 Cr | 37.00 Cr | 20.00 Cr | 27.00 Cr | 43.00 Cr | 52.00 Cr |
| Investing Cash Flow | -0 | -0 | -0 | -1.00 Cr | -1.00 Cr | -1.00 Cr | -70.00 Cr | -28.00 Cr | 15.00 Cr | -20.00 Cr | -33.00 Cr | -24.00 Cr |
| Financing Cash Flow | -0 | -1.00 Cr | -0 | 0 | -1.00 Cr | 1.00 Cr | -2.00 Cr | -15.00 Cr | -5.00 Cr | -4.00 Cr | -3.00 Cr | -1.00 Cr |
| Capital Expenditure | 0 | 0 | -1.00 Cr | -1.00 Cr | -1.00 Cr | -1.00 Cr | -2.00 Cr | -2.00 Cr | -2.00 Cr | -1.00 Cr | -1.00 Cr | -25.00 Cr |
| Free Cash Flow | 0 | 1.00 Cr | 0 | 1.00 Cr | 3.00 Cr | 6.00 Cr | 96.00 Cr | 35.00 Cr | 18.00 Cr | 26.00 Cr | 42.00 Cr | 27.00 Cr |
| Net Change in Cash | -0 | 0 | 0 | 1.00 Cr | 2.00 Cr | 7.00 Cr | 26.00 Cr | -6.00 Cr | 30.00 Cr | 3.00 Cr | 7.00 Cr | 28.00 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 5.3% | 11.8% | 18.8% | 21.7% | 26.1% | 27.6% | 65.6% | 44.4% | 45.2% | 43.2% | 51.0% | 36.6% |
| Net Margin % | 0.0% | 0.0% | 6.2% | 13.0% | 21.7% | 27.6% | 50.2% | 39.5% | 41.9% | 43.2% | 50.0% | 42.3% |
| ROE % | 0.0% | 0.0% | 9.1% | 16.7% | 22.7% | 25.0% | 86.4% | 20.9% | 13.4% | 14.3% | 17.8% | 18.5% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for 3BBLACKBIO
Price performance - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9iRUtPZHdELTdGdldraDV6T2thM1FkX2lWMkxqdks5Z0xrWDdUNDhKQWpnbFFrV0FxbTVwaktYLVlDcTVXY2dYSFVIQ01RZ0FldjFkWkRMX0VYTWo3cW5n?oc=5" target="_blank">Price performance</a> <font …
3BBLACKBIO Stock Price and Chart — NSE:3BBLACKBIO - TradingView
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE10d0lESXQxck5JdDgxQ1J3TzdzWmhJeXlGR1JXd2pnZEVudzU1NklaWEZhSmhDYmpyU2laM2YzRnhHaDNDbUROb21lcHh5NkVpOG00OVB1RTM2X0JZSVpGNg?oc=5" target="_blank">3BBLACKBIO Stock Price and Chart — NS…
3B Blackbio Dx Limited (3BBLACKBIO.NS) insider ownership and holdings - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE9LaTE4YzFpaUZXTGlZREo3ZDdRWElxYTV5eDhUNzRBNWdhOTVkVHl2Y1FobUVMRkt6dTJyUUF1cnkwVk5SdFd6emZ2eFJ6V05nVGFWWHl4OEhid0Nrb01nOVd3Tld3TzcwSV9xcFZEaXZKQQ?oc=5" target="_blank">3B Blackbio D…
Price to earnings forward of 3B BlackBio Dx Ltd – NSE:3BBLACKBIO - TradingView
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPRmJLem5qdUVQMlVRdUxLT2ZEVWV0WWdWZnNwYm1nT1g4NzA4aTZ0V3Z5cGRLNHM1Um5ZYm1vMURCZkZ0RVFlQng1cjd4V24zV3J1M0p5M2E3WUh3V2pYQ3V5SURtdk9hMzFGS2NPQkdaOUQybGQzS3lCZGVkcXJ6TENhYi1KMjd3WW1wbU…
3B Blackbio Dx Ltd 52 Week High Streak and Valuation View - Univest
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxObE1TempMVTdxdmhPUEZFd1F2dEM4NzM1dnUxUzBsZXFhNnVLX0t4M3FmUDNvbGQ2UGxYWDhFdnB2cko0eGxuYlVOQmY4MV9vbE5kYXpTQ0ttSEdOTDlsRDhnclBsMWFfMHVFU25Id3VsQ2RTaXFHMXdzQkxaVkx1UkowOUJNR2tmVkJIM2…
3B Blackbio Dx Q2 2026 Earnings: Revenue Climbs 47.11% YoY to ₹141.92 Crore, Yet Stock Slips 2.77% - siam.in
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQLVhMOVdfZnNaMDQ3LS1RT0NTQ3B1a1Blc0N3VG1uZlVleXp3WkNnQTZ6QWQ1X3lRUmdTNkxFYnYybXFUdVF6Z1VCZ2FYTW5zUTBHZnZmT3k4N2N2akFqS0FGcjJOZVRzZDJlQzhVVWdjMGpsaFlreTF6WGxpNVZBN2xtcnprcnIzbkhhZl…
3BBLACKBIO — Frequently Asked Questions
What is the current share price of 3B Blackbio Dx Limited (3BBLACKBIO)?
As of 2026-10-24 04:55 IST, 3B Blackbio Dx Limited (3BBLACKBIO) trades at ₹1,349.30 on NSE. Its 52-week range is ₹1,102.80 to ₹1,710.40.
What is the P/E ratio of 3BBLACKBIO?
3BBLACKBIO trades at a trailing price-to-earnings (P/E) ratio of 20.50. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 4.08.
Does 3BBLACKBIO pay a dividend?
3B Blackbio Dx Limited (3BBLACKBIO) currently offers a dividend yield of 0.31%.
What is the return on equity (ROE) of 3BBLACKBIO?
3BBLACKBIO has a return on equity (ROE) of 18.46%.
Is 3BBLACKBIO a good stock to buy?
This page provides a data-driven analysis of 3B Blackbio Dx Limited (3BBLACKBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.